Immuno-Oncology: How to Develop a Treatment Plan
|
|
- Juliana Sherman
- 5 years ago
- Views:
Transcription
1 Immuno-Oncology: How to Develop a Treatment Plan Wednesday, May 16 3:30 5:30 pm Note one action you ll take after attending this session: Karen Anderson, MN, RN, AOCNS, BMTCN, CRNI Clinical Operations Manager Bezos Family Immunotherapy Clinic Seattle Cancer Care Alliance kcanders@seattlecca.org Abigail Baldwin-Medsker, MSN, RN, OCN Memorial Sloan Kettering Cancer Center baldwina@mskcc.org Key Session Takeaways 1. Learner will identify potential treatment plan options for patients receiving immune-oncology. 2. Learner will identify two potential toxicities of CAR T-cell therapy and management strategies. 3. Learner will describe nursing considerations for a patient with financial toxicity. Preconference Oncology Nursing Society 43nd Annual Congress May 17 20, 2018 Washington, DC 1
2 ONS Pre Conference Immuno-Oncology: How To Develop a Treatment Plan Karen Anderson MN, RN, AOCNS, BMTCN, CRNI Abigail Baldwin-Medsker MSN, RN, OCN Disclosures No disclosures Preconference 1
3 Key Takeaways Learner will identify potential treatment plan options for patients receiving immune-oncology. Learner will identify two potential toxicities of CAR T cell therapy and management strategies. Learner will describe nursing considerations for a patient with financial toxicity. Cancer is smart, but your immune system is smarter. The body s own immune system provides one of the best defenses against cancer. Presentation Overview: How to Develop a Treatment Plan Definition of Immunotherapy Historical perspective & The Paradigm Shift Immuno-Oncology (IO) Symptom & Toxicity Profiles Safe Handling Patient and Caregiver Considerations Financial Implications Implications to Nursing Practice & the Future Preconference 2
4 Immunotherapy Harnesses the patient's own immune system to fight diverse cancer types (Bayer et al 2017) Four major categories: 1. Monoclonal Antibodies 2. Checkpoint Inhibitors 3. Oncolytic Viral Therapy 4. Chimeric Antigen Receptor T Cells Timeline of Events in the development of Immun oncology William Coley 1890 s BCG mouse studies TNFa BCG approval for bladder cancer TVEC approved for adv melanoma Cancer immunosur veillance 1957 Autologous BMT Allogeneic BMT Donor Lymphocyte Infusions Tumor Infiltrating Lymphocytes Rituximab (Anti CD20) mab Brentuximab Vedotin (Anti CD30) mab INF α IL Ginex, et al., 2017 Link b/t HIV Kaposi s sarcoma CAR T Therapies Checkpoint Inhibitors Ipilimumab Nivolumab Pembrolizumab Preconference 3
5 Paradigm Shift in Oncology- Immunotherapy How the Normal Immune System Functions How the Normal Immune System Functions: Overview of B cells & T cells B Cells B cell development B cell function T Cells T cell development T cell function NIH (2013); Murphy K. (2011). Preconference 4
6 Cell Mediated Immune Response Molnar, C. & Gair, J. (2015). Concepts of Biology 1 st Canadian Edition. [E version]. Accessed 1/7/18 at 3 adaptive immunity/. Licensed under Creative Commons Attribution 4.0 International License. Three E s of cancer immunoediting Used with permission, Dunn et al., Nature, 2002 New Approaches Target the Tumor Chemotherapy and AutoHCT Monoclonal Antibodies o Rituximab and Herceptin Antibody-Drug Conjugates o Brentuximab Tumor Checkpoint Blockade PD-L1 Target the Host Vaccination Oncolytic viruses Immune Modulators o Lenalidomide Immune Checkpoint Blockade o PD1, CTLA4 Target both Tumor + Host Allogeneic HCT Bispecific Antibodies Blinotumumab CAR T Therapy Oncolytic viruses Preconference 5
7 Immunotherapy Four major categories: 1. Monoclonal Antibodies 2. Checkpoint Inhibitors 3. Oncolytic Viral Therapy 4. Chimeric Antigen Receptor T Cells Case Study Case Study 65 yo male- Mike Presents with 10 pound weight loss, palpable L sided cervical lymph nodes, and progressive fatigue. CXR reveals mediastinal lymphadenopathy Labs: Unremarkable, with exception of LDH in the 700 s Bx of lymph node reveals DLBCL Pt begins treatment with R-CHOP x 6 cycles Preconference 6
8 Monoclonal Antibodies Monoclonal Antibodies (MoAbs) Substances that have the capability to act as a naturally made antibody within the human body but are created to target a specific antigen. Restore Enhance Mimic Bayer, V., Amaya, B., Baniewicz, D., Callahan, C., Marsh, L., et al. (2017) MoAbs by class Antibody/Agent Target Disease Side effect profile Trastuzumab (Herceptin) HER2 HER2 positive Breast Cardiac toxicity, pulmonary toxicity, HTN, thromboembolus, neutropenia, fatigue, skin reactions, diarrhea, acute infusion reactions Bevacizumab (Avastin) VEGF CR, NSCL, Renal Cardiac toxicity, pulmonary toxicity, HTN, thromboembolus, neutropenia, fatigue, skin reactions, diarrhea Cetuximab (Erbitux) EGFR H&N, CR Cardiac toxicity, acute infusion reaction, pulmonary toxicity, thromboembolus, neutropenia, fatigue, skin reactions, diarrhea Panitumumab (Vectibix) EGFR CR Cardiac toxicity, acute infusion reaction, pulmonary toxicity, thromboembolus, neutropenia, fatigue, skin reactions, diarrhea Ipilimumab (Yervoy) CTLA 4 Melanoma Enterocolitis, acute infusion reactions, endocrinopathies, diarrhea, fatigue Rituximab (Rituxan) CD20 NHL, CLL CRS, tumor lysis syndrome, mucositis, nausea, fatigue, SOB, neutropenia Adapted from Scott, A, Allison, J. & Wolchok, J., 2012, Preconference 7
9 New MoAB Approvals in 2017 Antibody/Agent Target Disease Side effect profile obinutuzumab (Gazyva ) Hu CD20 Advanced FL acute infusion reactions, tumor lysis, cytopenias, hep B virus reactivation, PML gemtuzumab ozogamicin (Mylotarg ) inotuzumab ozogamicin (Besponsa ) CD33 AML acute infusion reactions, hepatotoxicity, hemorrhage, infection, QT prolongation CD 22 B cell ALL acute infusion reactions, hepatotoxicity, cytopenias, infection, fatigue, hemorrhage Genentech, 2017; Pfizer Oncology, Check Point Inhibitors Checkpoint Inhibitors Use the immune system to fight cancer by unleashing T cells to attack cancer cells Prevent tumor from blocking T cell activity Adapted from Mellman et al., Nature 2011, with permission Preconference 8
10 Immune Checkpoints T cells have inhibitory and excitatory receptors Excitatory turn ON the T cell (gas) Inhibitory turn OFF the T cell (brake) Goal with immune checkpoint blockade is to BLOCK the inhibition of the T cell Release the brake, and allow the T cell to GO Drug Name Indications Anti CTLA4 Ipilimumab(YERVOY ) Unresectable or metastatic melanoma Adjuvant treatment melanoma Anti PD1 Nivolumab Unresectable or Metastatic Melanoma (OPDIVO ) Metastatic Non Small Cell Lung Cancer Renal Cell Carcinoma Classical Hodgkin Lymphoma Squamous Cell Carcinoma of the Head and Neck Urothelial Carcinoma Pembrilizumab Melanoma (KEYTRUDA ) Non Small Cell Lung Cancer Head and Neck Cancer Classical Hodgkin Lymphoma Urothelial Carcinoma Microsatellite Instability High Cancer Anti PDL1 Atezolizumab Locally Advanced or Metastatic Urothelial Carcinoma (Tecentriq ) Metastatic Non Small Cell Lung Cancer Avelumab Metastatic Merkel cell carcinoma (MCC) (BAVENCIO ) Locally advanced or metastatic urothelial carcinoma Durvalumab Locally advanced or metastatic urothelial carcinoma (IMFINZI ) Bristol Meyers Squibb company 2017; Merck Sharp & Dphme Corp ; EMD Serrano, 2017; Genentech, Inc. 2017; AztraZeneca 2017 Oncolytic Viruses Preconference 9
11 Oncolytic Viruses Oncolytic viral immunotherapy (OVI) is a viral targeted therapy that directly kills Four mechanisms of action are related cancer cells by causing tumor death, to OVIs: viral cell receptor response, producing tumor-toxic cytokines or cytokine release, nuclear replication, antitumor host immune responses and extracellular immune response Two ways viruses can be used in treatment: 1. As the sole therapy 2. As a vector for the delivery of the therapy Two types of OVIs are nonpathogenic (harmless to humans) and pathogenic (requiring genetic modification for use) Bayer et al., 2017 Oncolytic Viruses Examples Talimogene lahaerparepvec (T- VEC) -Modified Herpes Simplex Virus 1 (IMLYGIC ) Indication Advanced melanomas with injectable, unresectable tumor cutaneous, subcutaneous, nodal lesions Amgen, 2017 Case Study Preconference 10
12 Case Study Mike s lymphoma has progressed despite receiving R-CHOP x 6, salvage chemotherapy with RICE x3, and an Autologous HCT. He s referred to a tertiary cancer center for consultation for CAR-T cells. CAR T- Cells Chimeric Antigen Receptor (CAR) T Cells A type of adoptive cell therapy T-cells are genetically modified to express a chimeric antigen receptor (CAR) that binds to target antigens displayed on the tumor When binding occurs, T-cells are activated, leading to T- cell proliferation and differentiation, secretion of cytokines, and direct cell kill May persist and lead to immunologic memory for antigen Kalos, et al., 2011; Riddell, 2014 Preconference 11
13 CAR T cell manufacturing T Cell Selection/Activation Genetic modification (retroviral or lentiviral vectors) Expansion of T cells in culture ± Cryopreservation Zhang, et al., 2017 CAR T Cell Engineering Image credit: Jackson, H.J., Rafiq, S., and Brentjens, R.J. (2016). Driving CAR T cells forward. Nature Reviews Clinical Oncology,13, Used with permission. Antigen Targets in Clinical Trials Target Disease CD 19 Lymphoid malignancies BCMA Multiple Myeloma CD 20 NHL CD 22 NHL ROR1 CLL, MCL, ALL, TNBC, NSCLC GD2 Glioblastoma; Neuroblastoma; Sarcoma CEA Pancreatic CA; colorectal CA; hepatocellular CA PSCA; PSMA TGFβRDN Prostate CA EGFR Solid tumors Mesothelin Solid tumors HER2 Solid tumors Retrieved on 1/28/18 from Preconference 12
14 FDA Approved CAR T Cell Agents Agent Target Indication tisagenlecleucel CD 19 2 nd Relapse or refractory B cell ALL in (KYMRIAH ) pts up to age 25 Axicabtagene ciloleucel (YESCARTA ) CD 19 Relapsed or refractory aggressive NHL (after 2 lines of therapy) in patients over age 18 Kite pharma, 2017; Novartis, 2017 CAR T Cell Therapy Logistics Center Selection Clinical trials at select centers Limited certified sites for FDA approved agents Relocation may be required Requirements to stay near treating center during and after therapy for monitoring Assess caregiver requirements Insurance clearance CAR T Cell Treatment Overview Treatment eligibility & consenting Leukapheresis CAR T cell manufacturing Pre Treatment CAR T Cell Therapy Lymphodepleting chemo CAR T Cell Infusion Toxicity monitoring (intensively for 4 weeks post) Disease re staging Long term follow up Post Treatment Preconference 13
15 Models of Care for CAR T Cells Inpatient Most common approach Hospitalization for cell infusion and post infusion monitoring for 7 days Discharge to OPD following therapy after pre defined monitoring period or resolution of toxicities Outpatient Ability to rapidly access trained inpatient and emergency care Frequent visits post infusion Close proximity to treating center (w/in 2hrs) post infusion Patient & caregiver education (wallet cards) Kymriah REMS, 2017; Yescarta REMS, 2017 CAR T Cell Infusion Lymphodepleting chemotherapy Fludarabine 30mg/m2 & Cyclophosphamide mg/m2 common Chemo given to create immunological space to allow expansion of CAR T cells CAR T cell infusion Generally 2 days after lymphodepletion Cells are infused intravenously, usually over 30 minutes or faster by gravity Premedicate w/ acetaminophen & diphenhydramine. Cells defrosted for infusion, chain of custody verifications Central lines recommended. Acute infusion reactions may occur, though uncommon Kalos & June, 2013; Novartis, 2017; Kite, 2017 Case Study Preconference 14
16 Developing a Treatment Plan: Symptom & Toxicity Profiles Determining severity: Grading irae Common Terminology Criteria for Adverse Events (CTCAE): Definition: An objective and consistent method for measuring side effects. Grading 1. Grade 1-Mild 2. Grade 2- moderate 3. Grade 3-severe 4. Grade 4- life-threatening 5. Grade 5- fatality CAR T Cells Toxicities and Side Effects Preconference 15
17 Common Toxicities of CAR T Cells Neurotoxicity 65% Tisagencleucel 87% Axicabtagene Ciloleucel (all grades) Infections Tumor Lysis Syndrome On target, off tumor toxicities Cytokine Release Syndrome (CRS) 79% Tisagencleucel 94% Axicabtagene Ciloleucel (all grades) Image Credit: Alex Ritter, Jennifer Lippincott Schwartz and Gillian Griffiths. (2015). Killer T cells surround a cancer cell. National Institutes of Health. Licensed under a CC BY NC 2.0. Brudno & Kochenderfer, 2016.; Kymriah REMS, 2017; Yescarta REMS, 2017 CRS Toxicities by Organ System Image credit: Brudno, J. & Kochenderfer, J. (2016). Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood, 127; Used with permission. Cytokine Release Syndrome Grade Toxicity Management Grade 1 Non life threatening (fever, nausea, etc) Supportive care Assess for/treat infection Admission generally indicated for fever Grade 2 Moderate interventions required (ex: oxygen support, supportable hypotension, moderate organ toxicity) Supportive care ICU may be indicated if pressors Consider Tocilizumab 8mg/kg (max dose 800mg/dose), repeat dosing if needed ± Corticosteroids for high risk patients Grade 3 Grade 4 Grade 5 Aggressive interventions required (ex: O2 needs 40%, severe organ toxicity, severe hypotension) Life threatening sx (ex: intubation, severe organ toxicity) Death Supportive care ICU level care usually required Tocilizumab 8mg/kg (max 800mg/dose), repeat if necessary ± Corticosteroids (Dexamethasone 10mg IV q 6 hours or Methylprednisolone 1mg/kg q 12hrs) Supportive care ICU level care required Tocilizumab 8mg/kg (max 800mg/dose), repeat if necessary ± Corticosteroids (Methylprednisolone 1gm daily) Adapted from Lee, D.W., et al. (2014); Kymriah REMS, 2017; Yescarta REMS, 2017 Preconference 16
18 Supportive Care: CRS VS frequently Continuous pulse ox or telemetry may be warranted Grade 2 Frequent physical and neurological exams Fever: R/O infection; anti-pyretics prn if febrile Prophylactic abx and anti-virals Follow labs & serum inflammatory markers Ex: CBC, CMP, Coags, CRP, Ferritin, IL-6 Monitor I/O, weights Hypotension: Fluids to maintain MAP, vasopressors Transfuse as needed for coagulopathies, anemia, thrombocytopenia Neutropenia- GCSF used by some centers Oxygen support as needed Severe toxicities may require dialysis, mechanical ventilation Brudno & Kochenderfer, 2016.; Kymriah REMS, 2017; Yescarta REMS, 2017 Neurotoxicity Can occur w/ or w/o CRS, but more often in conjunction with or after CRS onset Pathophysiology hypothesized to be due to endothelial activation and cytokines crossing the blood brain barrier. May be mild to severe Headaches Anxiety Aphasia Encephalopathy Dizziness Tremor Seizures Delirium Cerebral edema Turtle, et al., 2017; Gust, et al, 2017; Kymriah REMS, 2017; Yescarta REMS, 2017 Neurotoxicity Grading CTCAE v4.0 Terms Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Somnolence Mild but more than usual drowsiness or sleepiness Moderate sedation; limiting instrumental ADL Obtundation or stupor Life-threatening consequences; urgent intervention indicated Death Dizziness Mild unsteadiness or sensation of movement Moderate unsteadiness or sensation of movement; limiting instrumental ADL Severe unsteadiness or sensation of movement; limiting self care ADL - - Tremor Mild symptoms Moderate symptoms; limiting Severe symptoms; limiting instrumental ADL self care ADL - - Headache Mild pain Moderate pain; limiting instrumental ADL Severe pain; limiting self care ADL - - Encephalopathy Seizure Mild symptoms Brief partial seizure; no loss of consciousness Life-threatening Moderate symptoms; limiting Severe symptoms; limiting consequences; urgent instrumental ADL self care ADL intervention indicated Life-threatening; Multiple seizures despite prolonged repetitive Brief generalized seizure medical intervention seizures Death Death Edema cerebral Adapted from National Cancer Institute CTCAE Grading criteria v. 4.03, Life-threatening consequences; urgent intervention indicated Preconference 17
19 Neurotoxicity Management Supportive care Sz precautions, anti-sz meds prophylactically Aspiration precautions Transfer to ICU for severe toxicities (ie: ICP monitoring) R/O other etiologies of neurologic abnormalities (ex: MRI, CT, EEG, LP) If concurrent CRS, administer IL-6 Blockade (Tocilizumab) Corticosteroids- Treat according to institutional algorithm or REMS guidelines For Grade 2-3: Dexamethasone 10mg IV q 12hrs to 6hrs For Grade 4: Methylprednisolone 1 gm/daily x 3 Yescarta REMS, 2017; Neelapu, et al., 2017 Long-term Monitoring Hypogammaglobulinemia with CD 19 CAR T Disease restaging and monitoring for relapse Long-term follow-up FDA- 15 year f/u for patients treated with replication-competent viral vectors Monitoring for secondary malignancies FDA, 2016 Monoclonal Antibodies (MoAbs) Toxicities and Side Effects Preconference 18
20 MoAbs by class Antibody/Agent Target Disease Side effect profile Trastuzumab (Herceptin) HER2 HER2 positive Breast Cardiac toxicity, pulmonary toxicity, HTN, thromboembolus, neutropenia, fatigue, skin reactions, diarrhea, acute infusion reactions Bevacizumab (Avastin) VEGF CR, NSCL, Renal Cardiac toxicity, pulmonary toxicity, HTN, thromboembolus, neutropenia, fatigue, skin reactions, diarrhea Cetuximab (Erbitux) EGFR H&N, CR Cardiac toxicity, acute infusion reaction, pulmonary toxicity, thromboembolus, neutropenia, fatigue, skin reactions, diarrhea Panitumumab (Vectibix) EGFR CR Cardiac toxicity, acute infusion reaction, pulmonary toxicity, thromboembolus, neutropenia, fatigue, skin reactions, diarrhea Ipilimumab (Yervoy) CTLA 4 Melanoma Enterocolitis, acute infusion reactions, endocrinopathies, diarrhea, fatigue Rituximab (Rituxan) CD20 NHL, CLL CRS, tumor lysis syndrome, mucositis, nausea, fatigue, SOB, neutropenia (Scott, A, Allison, J. & Wolchok, J., 2012) MoAbs: Side Effects Hypersensitivity Reactions Cardiac Toxicity Pulmonary Toxicity HTN Diarrhea Fatigue Entrocolitis Tumor Lysis CRS (Bayer, V., Amaya, B., Baniewicz, D., Callahan, C., Marsh, L., et al., 2017) Checkpoint Inhibitors Toxicities and Side Effects Preconference 19
21 Checkpoint Inhibitors: Side Effects & Toxicities Based on the mechanism of action, there is potential for autoimmune activity in any organ system. Immune-Related Adverse Effects (iraes) include: Dermatitis Colitis Pneumonitis Hepatitis 6 3 Immune-related Adverse Events (iraes) hypophysitis pneumonitis sinusitis enteritis colitis Pancreatitis/ autoimmune diabetes \ Adrenal insufficiency uveitis thyroiditis myocarditis hepatitis dermatitis arthralgia/ myalgia Basic irae Management Principles Assess signs and symptoms Determine cause (rule out non-inflammatory causes) Severity via common terminology criteria for adverse events (CTCAE) Identify appropriate intervention Ongoing surveillance Preconference 20
22 General Management by Grade Grade Management Follow up Grade 1 Monitor patient closely Begin surveillance calls/labs. Grade 2 Delay of treatment Initiate an oral corticosteroid (1mg/kg) for 4 6 weeks Continue surveillance; taper steroids slowly. Grade 3/4 Higher corticosteroid dose (2mg/kg) May require admission for IV steroids and/or IV hydration Consider admission; post admission surveillance. Adapted from CTCAE Grading criteria v Oncolytic Viral Therapy Toxicities and Side Effects Side Effects and Toxicities Neurologic Fatigue, chills, fever, headache, dizziness Cardiac Pulmonary Gastrointestinal Renal Infectious Disease Musculoskeletal Dermatologic Metabolic Miscellaneous Vasculitis Flu like symptoms, pneumonitis Nausea, vomiting, diarrhea, constipation, abdominal pain, oral herpes Glomerulonephritis Herpes infections, systemic bacterial infection, cellulitis Myalgias, arthralgias, pain in extremity Necrosis, tumor tissue ulceration, impaired wound healing, and worsening psoriasis or vitiligo Weight loss Fever, pain at injection site Amgen, 2017 Preconference 21
23 Side effects More than 25 % of patients experience Fatigue, chills, fever, Flu-like symptoms, pain at injection site Pyrexia, chills, and influenza-like illness can occur at any time (more frequent first 3 months) Cellulitis-most common grade 3 side event Premedication with acetaminophen TVEC is sensitive to acyclovir, in the event of herpetic infection Amgen, 2017 Virus Precautions Protect against accidental spread. Perform adequate hygiene; cover area with a non permeable bandage Precautions: pregnant women, children, immunocompromised individuals should avoid contact with the site/drug. Avoid close contact with immunocompromised individuals In treatment settingscontact isolation, staff education, PPE Wall, L. & Baldwin Medsker, A. (2017) Developing a Treatment Plan: Safe Handling and Administration Preconference 22
24 Safe Handling and Administration Lack of published evidence based guidance on the safe handling and administration of most immunotherapy agents ASCO/ONS chemotherapy administration standards (Neuss, et al., 2016) Chemotherapy and Biotherapy Guidelines and Recommendations (Polovich, Olsen & LeFebvre., 2014). Education & Competencies Wiley, K. et al., 2017 Developing a Treatment Plan: Financial Implications Defining Financial Toxicity High costs of cancer care, even in patients with insurance, can lead to poorer outcomes, decrease quality of life, heighten stress and in some cases increase mortality rates Chino et al., (2017). Preconference 23
25 Statistics 13% of nonelderly patients spend at least 20% of their income on out-of-pocket expenses 50% of Medicare beneficiaries pay at least 10% of their income core treatment and out-ofpocket costs Zafar, Y.S., Financial Toxicity of Immunotherapies Melanoma- Ipilumumab/Nivolumab $256,000 per year Sarcoma Ipilumumab/Nivolumab $46,704 per dose; $186, 816 total Nivolumab $1830 per dose; total cost $47,580 per year Lymphoma (NHL)- Axicabtagene Ciloleucel (YESCARTA ) $373,000 per dose Brentuximab $294,000 per year GI- Pembrolizumab $16,470 per dose; total cost $148,230 M. Lee Teh, personal communication. Jan. 5, 2018; Babashov, V. et al., 2017; ICER, Financial Toxicity- CAR T Cells Complex and rapidly evolving insurance authorization processes Many payers still defining medical policy and approaches to coverage Intensive institutional financial coordination needed at time of referral to certified center Preconference 24
26 Financial Toxicity s Implications on Care Compliance Oral regimens Lower quality of life (Fenn, et al., 2017) Preventing Financial Toxicity and the Future Transparency Screen Document Offer resources Advocate ONS Tool Kit pdf Pirschel, C., 2017 Financial Assistance Programs Cancer Financial Assistance Coalition Cancercare Financial Assistance Program HealthWell Foundation Leukemia and Lymphoma Society American Cancer Society Expanded Access (Compassionate Use). FDA.gov. Jan. 20, Preconference 25
27 Financial Assistance Programs- RX Compassionate Use Patient Free Supply Co-pay Assistance Expanded Access (Compassionate Use). FDA.gov. Jan. 20, Case Study: Financial Toxicity Developing a Treatment Plan: Patient and Caregiver Considerations Preconference 26
28 Patient and Caregiver Considerations: Education Education Multimodality treatments/ combination therapy Response to immunotherapy compared to traditional therapies Toxicities differ from Chemotherapy Early side effect recognition and open communication with staff Patient and Caregiver Considerations: Education & Toxicity Management Should be pertinent to the type of Immunotherapy Safety Oriented Encouraged to report symptoms promptly Evidence based & patient & family centered Safety Drug specific Patient Evidence Based Communication 85 CAR T Cell Patient Education Needs Central line Birth control precautions Wallet card Refrain from driving and hazardous occupations for 8 weeks post treatment Proximity to center & f/u visit requirements after treatment Novartis, 2017; Kite, 2017 Photo courtesy of Seattle Cancer Care Alliance. Used w/ permission Preconference 27
29 Patient and Caregiver Considerations Coordination Access Multi Center Coordination Treatment schedules Infection control considerations Access to emergent care in case of toxicity Clinical Trials Psychosocial Anxiety r/t efficacy and the unknown Stress R/T diagnosis, disease progression, hospitalizations, deterioration in quality of life Impact on QOL Patient and Caregiver Considerations: Survivorship & Long Term Follow up Late Effects Palliative Care ONS Research Agenda Patient and Caregiver Considerations: The Nurse s Role Educator Coordinator of care Chairside/bedside Assessment Administration Understanding both of IO agents AND toxicity management Patient/caregiver support and advocate Multidisciplinary approach Preconference 28
30 Development of a Treatment Plan: Implications of IO on Nursing & the Future Implications of IO for Nursing Practice Urgent need to educate nurses to empower and ensure evidence based delivery of care. Opportunity to contribute to the development of evidence to ensure the delivery of patient centered care. Implications of IO for Nursing Practice: The Future Research on symptom management & quality of life Patient reported outcomes (PROs) Clinician vs Patient perspective Late effects of immunotherapy Survivorship Preconference 29
31 Acknowledgements Special Thanks To: Seattle Cancer Care Alliance leadership and staff Bezos Family Immunotherapy Clinic Staff University of Washington BMT & Heme-Onc Platinum services Fred Hutch program in Immunology Kathleen Shannon-Dorcy, PhD, RN, SCCA Director of Clinical/Nursing Research, Education and Practice Drs. David Maloney, Cameron Turtle, and Stan Riddell Contact: Karen Anderson Acknowledgements Special Thanks To: Mimma Errante, MS NP-C OCN Clinical Trials NP Ruth-Ann Gordon, MSN FNP-BC OCN Clinical Trials Nurse Coordinator, MSKCC Memorial Sloan Kettering Cancer Center Department of Nursing Contact: Abi Baldwin-Medsker Questions Preconference 30
32 References Amgen (2017). Talimogene lahaerparepvec (T-VEC). [Package insert]. Retrieved from AztraZeneca (2017). Imfinzi (durvalumab) [Package insert]. Retrieved from Babashov, V., Begen, M.A., Mangel, J., Zaric, G.S. (2017). Economic evaluation of brentuximab vedotin for persistent Hodgkin's lymphoma. Current Oncology, 24(1), e6 e14. Bayer, V., Amaya, B., Baniewicz, D., Callahan, C., Marsh, L., & McCoy, A. S. (2017). Cancer immunotherapy: An evidence-based overview and implications for practice. Clinical Journal of Oncology Nursing, 21(2), Bristol-Myers Squibb. (2011). Yervoy (ipilimumab) [US package insert]. Retrieved from Brudno, J., & Kochenderfer, J. (2016). Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood : Journal of the American Society of Hematology., 127(26), References Chino, F., Pepercorn, J.M., Rushing, C., Kamal, A.H., Alotmare, I., Samsa, G., & Zafar, S. Y. (2017) Out-of pocket costs, financial distress and underinsurance in cancer care. JAMA Oncology, 3(11), Dunn, GP; Bruce, AT; Ikeda, H; Old, LJ; & Schreiber, RD. (2002). Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology, 3, EMD Serano, Inc. (2017). Bavencio (avelumab). [Package insert]. Retrieved 1/28/18 from Expanded Access (Compassionate Use). U.S Food & Drug Administration. [FDA.gov.] Retrieved 1/20/2018 from m Fenn, K., Evans, S., McCorkle, R., DiGiovanna, M.P., Pusztai, L., Sanft, T., Chagpar, A. B. (2014). Impact of financial burden of cancer on survivors quality of life. Journal of Oncology Practice, 10(5), References Food and Drug Administration. (2006). Guidance for Industry: Gene therapy clinical trials- Observing subjects for delayed adverse events. Retrieved 1/28/18 from ularandgenetherapy/ucm pdf. Genentech, Inc. (2017). Tecentriq (atezolizumab) [Package insert]. Retrieved from Genentech, Inc. (2017). Gazyva (obinutuzumab). [Package insert]. Retrieved 1/28/18 from Ginex, P., Brassil, K., & Ely, B. (2017). Immunotherapy: Exploring the state of the science. Clinical Journal of Oncology Nursing, 21(2), Gust, J., Hay, K.A., Hanafi, L-A., Li, D. Myerson, D. and Turtle, C. (2017). Endothelial activation and blood brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discovery, 7 (12), Institute of Clinical and Economic Review (ICER). (2017). Chimeric antigen receptor T-cell therapy for B cell cancers: Effectiveness and value (Draft evidence review). Retrieved 1/28/18 from Preconference 31
33 References Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine, 3(95), 95ra73. Kalos, M., & June, C. H. (2013). Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity, 39(1), 10. Kite Pharma (2017). Yescarta (axicabtagene ciloleucel) [Package insert]. Retrieved 1/28/18 from Kite Pharma (2017). Yescarta (axicabtagene ciloleucel) Risk Evaluation and Mitigation Strategy. Retrieved 1/28/18 at Lee, D.W., Gardner, R., Porter, D.L., Louis, C. U., Ahmed, N., Jensen, M., Mackall, C.L. (2014). Current concepts in the diagnosis & management of cytokine release syndrome. Blood, 124(2), Mellman, I; Coukos, G; & Dranoff, G. (2011). Cancer immunotherapy comes of age. Nature, 480(7378), Merck Sharp & Dohme Corp. (2016). Keytruda (pembrolizumab) [Package insert]. Retrieved from References M. Lee Tee. [Personal Communication]. Jan. 5, Molnar, C. & Gair, J. (2015). Concepts of Biology- 1 st Canadian Edition. [E-version]. Accessed 1/7/18 at Murphy, K. (2011). Janesway Immunology. Garland Science. Eight edition. National Cancer Institute. (2010). Common Terminology Criteria for Adverse Events v4.03. NIH publication # Retrieved 1/28/18 from 14_QuickReference_5x7.pdf Neelapu, S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F.,... Shpall, E. (2017). Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nature Reviews., 15(1), Neuss, M. N., Gilmore, T. R., Belderson, K.M., Billett, A. L., Conti-Kalchik, T., Harvey, B.E., Polovich, M. (2016) Updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology. Journal of Oncology Practice, 12(12), Novartis. (2017). Kymriah (tisagenlecleucel). [Package insert]. Retrieved 1/28/18 from References Novartis. (2017). Kymriah (tisagenlecleucel). Risk evaluation and mitigation strategy. Retrieved 1/28/18 from Pirschel, C. (2017). Financial toxicity and its burden on cancer care. ONS Voice. 32(11), Pfizer Oncology. (2017). Besponsa (inotuzumab ozogamicin) [Package insert]. Retrieved 1/28/18 from Pfizer Oncology. (2017). Mylotarg (gemtuzumab ozogamicin) [Package insert]. Retrieved 1/28/18 from Polovich, Olsen & LeFebvre. (2014). Chemotherapy Biotherapy Guidelines and Recommendations for Practice: 4 th edition. Oncology Nursing Society. Riddell, S.R., Sommermeyer, D., Berger, C., Liu, L.S., Balakrishnan, A., Salter, A., Turtle, C.J. (2014). Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. The Cancer Journal, 20(2), Preconference 32
34 References Scott, A, Allison, J. & Wolchok, J. (2012). Monoclonal antibodies in cancer therapy. Cancer Immunity,12, 14. Turtle, C. J, Hay, K. A., Gust, J., Hanafi, L-A., Li, D., Liles, W.C., Maloney, D. G. (2017). Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells. Journal of Clinical Oncology, 35(15), suppl; Understanding the immune system: How it works. (2003). US Department of Health and Human Services National Institute of Health. NO Wall, L. and Baldwin-Medkser, A. (2017) Safe and effective standard of care. Clinical Journal of Oncology Nursing, 21(5), E1-E7. Wiley, K., LeFebvre, K. Wall, L., Baldwin-Medkser, A., Nguyen, K., Marsh, L., and Baniewicz, D. (2017). Immunotherapy administration. Clinical Journal of Oncology Nursing, S21(2), 5-6. Zafar, S. Y. (2016). Financial toxicity of cancer care: Its time to intervene. Journal of the National Cancer Institute, 108(5), djv370. Zhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017). Engineering CAR-T cells. Biomarker Research, 5, 22. Preconference 33
REMS Program Live Training FOR TRAINING PURPOSES ONLY
REMS Program Live Training FOR TRAINING PURPOSES ONLY This educational module contains information on selected YESCARTA -associated adverse reactions, including cytokine release syndrome and neurologic
More informationCANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center
CANCER IMMUNOTHERAPY 2018 Presented by John A Keech Jr DO MultiCare Regional Cancer Center Successful anti-cancer immunity is autoimmunity Green, The Scientist, 2014 Immunotherapy strategies Cancer vaccines
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationEngineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL
Engineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL Diana Schreier, Pharm.D., M.B.A. Pharmacy Grand Rounds October 17, 2017 2017 MFMER
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationCytokine Release Syndrome and Neurotoxicity
Cytokine Release Syndrome and Neurotoxicity Colette Chaney, RN,BSN,OCN Clinical Research Operations Manager Clinical Research Nurse Objectives Describe signs and symptoms of cytokine release syndrome and
More informationImmunotherapy Overview, Rationale, and Role in Clinical Practice
Immunotherapy Overview, Rationale, and Role in Clinical Practice Financial Disclosure Bradi L. Frei, PharmD, BCOP, BCPS has no relevant financial relationships with commercial interests to disclose. OBJECTIVES
More informationIMMUNE EFFECTOR CELLS: CAR T AND OTHER CYTOTOXIC EFFECTOR CELLS OF THE IMMUNE SYSTEM
IMMUNE EFFECTOR CELLS: CAR T AND OTHER CYTOTOXIC EFFECTOR CELLS OF THE IMMUNE SYSTEM Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies
More informationIMMUNOTHERAPY FOR LUNG CANCER
IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Lung Cancer Basics... 2 Immunotherapy... 3 FDA Approved Immunotherapies...
More informationImmune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy
Immune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy Philip Mease MD Director, Rheumatology Clinical Research, Swedish- Providence St. Joseph Health Clinical Professor, University of Washington
More informationMelanoma Immunotherapy. Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management
Melanoma Immunotherapy Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management Mike Buljan, NP UCSF Medical Center Melanoma Oncology Disclosures None Only FDA-approved
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationCAR-T. Subrena Powell RN, MSN, BMTCN
CAR-T Subrena Powell RN, MSN, BMTCN Objectives Discuss the treatment timeline of a patient receiving CAR-T therapy Describe the side effects and management of symptoms of CAR-T therapy Treatment Schema
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationExample Clinician Educational Material for Providers of Immune Effector Cellular Therapy
Example Clinician Educational Material for Providers of Immune Effector Cellular Therapy Disclaimer: This example is just one of many potential examples of clinician education material that can be provided
More informationLecture 17: Vaccines (Therapeutic and Prophylactic Types)
Lecture 17: Vaccines (Therapeutic and Prophylactic Types) Therapeutic vaccines Bacillus Calmette Guerin (BCG; TheraCys) Very old agent initially developed as vaccine for MTB. Uses: Superficial bladder
More informationCAR-T Therapy: The Past, The Present, and The Future. Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center
CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Objectives Review indications for FDA approved CAR-T therapy
More informationObjectives. Emily Whitehead 10/11/2018. Chimeric Antigen Recepetor T-Cells (CAR-T) CAR-T Therapy: The Past, The Present, and The Future
Objectives CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Review indications for FDA approved CAR-T therapy
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
More informationManagement of Immune Checkpoint Inhibitor Related Toxicities
Management of Immune Checkpoint Inhibitor Related Toxicities Katie Wolfram, PharmD Clinical Pharmacist, Oncology Memorial Hospital of South Bend A Webinar for HealthTrust Members November 12, 2018 Disclosures
More informationThe KYMRIAH Experience
The KYMRIAH Experience INDICATION KYMRIAH (tisagenlecleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell
More informationYESCARTA (axicabtagene ciloleucel)
YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY
ENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY Lauren Clarine DO, Renil Rodriguez Martinez MD, Matthew Levine MD, Amy Chang MD, and Megan McGarvey MD May 6, 2017 Immune checkpoint inhibitors
More informationIMMUNOTHERAPY OVERVIEW. Gloria Roldan Urgoiti MD, MSc, FRCPC Tom Baker Cancer Centre April 22, 2017
IMMUNOTHERAPY OVERVIEW Gloria Roldan Urgoiti MD, MSc, FRCPC Tom Baker Cancer Centre April 22, 2017 Faculty/Presenter Disclosure Speaker: Dr. Gloria Roldan Urgoiti Relationships with commercial interests:
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationImmunotherapies. Supporting health professionals to safely care for patients receiving immunotherapy in the cancer setting.
Immunotherapies Supporting health professionals to safely care for patients receiving immunotherapy in the cancer setting. INDEX Select a topic below for more information Principles of immunotherapy Classes
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationCAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes. Shannon L.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes Shannon L. Maude, MD, PhD CTL019 cell Lentiviral vector Anti-CD19 CAR construct CD19 Native
More informationNEW FDA DRUG APPROVALS
NEW FDA DRUG APPROVALS Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies Las Vegas, NV March 15, 2018 Disclosures We have nothing
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More information-- Manufacturing Success Rate of 99 Percent in ZUMA-1 Pivotal Trial with a Median 17 Day Turnaround Time --
Kite s Yescarta (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationCAR T-Cell Therapy for Your Patients: What You Need To Know
CAR T-Cell Therapy for Your Patients: What You Need To Know Marco L. Davila, MD, PhD Associate Member, Blood & Marrow Transplantation and Cellular Immunotherapy Medical Director Cell Therapy Facility H.
More informationYervoy. Yervoy (ipilimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 4 Last Review Date: March 18, 2016 Yervoy Description Yervoy (ipilimumab)
More informationYescarta (axicabtagene ciloleucel)
Last Review Date: March 30, 2018 Effective Date: April 1, 2018 Number: MG.MM.PH.42 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider
More information9/22/2016. Introduction / Goals. What is Cancer? Pharmacologic Strategies to Treat Cancer. Immune System Modulation
Immunomodulatory Therapies in Cancer Treatment Bill O Hara, PharmD, BCPS, BCOP Advanced Practice Pharmacist, Oncology/BMT Thomas Jefferson University Hospital Introduction / Goals What is Cancer? How can
More informationOncologic Emergencies: Cancer Immunotherapy-Related Adverse Events in the Emergency Department
Oncologic Emergencies: Cancer Immunotherapy-Related Adverse Events in the Emergency Department Daniel Pallin, MD, MPH Assistant Professor of Emergency Medicine Harvard Medical School Research Director,
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationCAR T CELL IMMUNOTHERAPY FOR ALL. Stephan Grupp, MD, PhD
CAR T CELL IMMUNOTHERAPY FOR ALL Stephan Grupp, MD, PhD Disclosures Research and/or clinical trial support from Novartis, Servier, Vertex and Kite Study steering committees, consulting, or scientific advisory
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationExploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies
Exploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies Maurice Alexander, PharmD, BCOP, CPP Clinical Specialist, Blood and Marrow Transplant UNC Bone Marrow
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationRituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description
More informationimmunotherapy a guide for the patient
immunotherapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2 immunotherapy... 5 Checkpoint Inhibitors... 6-9 Monoclonal Antibodies... 9 Vaccines... 10 Adoptive T-Cell
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 5 Last Review Date: June 24, 2016 Keytruda Description Keytruda (pembrolizumab)
More informationGENETICALLY ENHANCED CANCER THERAPIES
GENETICALLY ENHANCED CANCER THERAPIES Hello! I am Tapani Ronni Science talks to translators and interpreters since 2012. You can find me at: www.polarbearcommunications.com ATA 2018 2 About the speaker
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More information4100: Cellular Therapy Essential Data Follow-Up Form
4100: Cellular Therapy Essential Data Follow-Up Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: Visit: 100 day 6 months 1 year 2 years >2 years, Specify:
More informationYervoy. Yervoy (ipilimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 5 Last Review Date: September 15, 2017 Yervoy Description Yervoy (ipilimumab)
More informationCAR-T CELLS: NEW HOPE FOR CANCER PATIENTS
CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS Natasha Kekre, MD, MPH, FRCPC Hematologist, Blood and Marrow Transplant Program, TOH Associate Scientist, Ottawa Hospital Research Institute Assistant Professor
More informationCancer Immunotherapy Future from the Past?
Disclaimer This talk is intended for educational value, and includes comments on unlicensed drugs. Please liaise with a specialist if you have a clinical query. Cancer Immunotherapy Future from the Past?
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More informationNew Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors
New Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors Farah Brasfield, MD Chair, Regional Chiefs of Oncology Kaiser Permanente Jennifer Chang, PharmD, MPH Supervisor, Drug Information Services
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationWhat should I ask my treatment team?
TREATMENT TRANSFORMED Child portrayed is not a real KYMRIAH patient. DISCUSSION GUIDE What should I ask my treatment team? Making treatment decisions for relapsed or refractory cancer can be hard. Asking
More informationImmunotherapy. Professor Nicola Stoner Consultant Cancer Pharmacist ASPCP Birmingham 15 th November 2018
Immunotherapy Professor Nicola Stoner Consultant Cancer Pharmacist ASPCP Birmingham 15 th November 2018 Introduction What is immunotherapy? Immune system refresher Immunotherapy Treatments Monoclonal antibodies
More informationNursing Perspective on iraes: Patient Education, Monitoring and Management
Nursing Perspective on iraes: Patient Education, Monitoring and Management Rebecca Lewis, CRNP Nurse Practitioner University of Pittsburgh-HCC Shadyside Disclosures No relevant financial relationships
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationUnderstanding your treatment and the side effects you may experience
Understanding your treatment and the side effects you may experience What does treat? is a prescription medicine used in combination with YERVOY to treat a type of skin cancer called melanoma that has
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationManaging Checkpoint Inhibitor Toxicities. Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute
Managing Checkpoint Inhibitor Toxicities Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute Approved Indications Ipilimumab Nivolumab Pembrolizumab* Atezolizumab Avelumab Durvalumab Ipi + Nivol
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More informationCheckpoint inhibitors: Strategies to checkmate T-cell mediated toxicity. Disclosure Statement. Learning Objectives
Checkpoint inhibitors: Strategies to checkmate T-cell mediated toxicity Adam J. DiPippo, PharmD Clinical Pharmacy Specialist Leukemia Texas Society of Health-System Pharmacists 2017 Annual Seminar April
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationORIEN NOVA TEAM SCIENCE AWARD
ORIEN NOVA TEAM SCIENCE AWARD CALL FOR LETTERS OF INTENT BACKGROUND: The Oncology Research Information Exchange Network (ORIEN) is a unique alliance to integrate data sharing and collaborative learning
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Emily Borders, Pharm.D., M.S., BCOP Oncology Clinical Pharmacist Stephenson Cancer Center Faculty Disclosure Learning Objectives
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationBristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
January 20, 2017 Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer (PRINCETON, NJ, January 19, 2017) - Bristol-Myers Squibb Company (NYSE: BMY) announced that it has decided not
More informationGAZYVA Dosing and Administration Guide
GAZYVA Dosing and Administration Guide Indications GAZYVA is a CD20-directed cytolytic antibody and is indicated: In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at
More informationCheckpoint Blockade in Hematology and Stem Cell Transplantation
Checkpoint Blockade in Hematology and Stem Cell Transplantation Saad S. Kenderian, MD Assistant Professor of Medicine and Oncology Mayo Clinic College of Medicine October 14, 2016 2015 MFMER slide-1 Disclosures
More informationWhat Is Cancer Immunotherapy?
Cancer Immunotherapy Immunotherapy is treatment that uses your body's own immune system to help fight cancer. Get information about the different types of immunotherapy and the types of cancer they are
More informationNEW FDA DRUG APPROVALS
NEW FDA DRUG APPROVALS Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies Las Vegas, NV March 15, 2018 Disclosures We have nothing
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationOpdivo (nivolumab) An overview of Opdivo and why it is authorised in the EU. What is Opdivo and what is it used for?
EMA/852560/2018 EMEA/H/C/003985 An overview of Opdivo and why it is authorised in the EU What is Opdivo and what is it used for? Opdivo is a cancer medicine used to treat the following: melanoma, a type
More informationBESPONSA (inotuzumab ozogamicin)
BESPONSA (inotuzumab ozogamicin) Fact Sheet BESPONSA (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody (mab) targeting CD22, a cell surface antigen expressed
More informationACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy
ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy
More informationDurable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics Timothy Cloughesy, MD University of California, Los Angeles Disclosure 2 FDA Endpoints for the Approval of Cancer
More information